We wish to thank Lavoie and colleagues for their thoughtful letter. We agree with their suggestion that interventions in behavioral medicine be viewed analogously to phase 1, 2, and 3 clinical trials in drug development and thank them for pointing out the recommendations of the Office of Behavioral and Social Science Research.
Berkowitz SA, Johansen KL. Behavioral Medicine Trial Design: Time for a Change—Reply. Arch Intern Med. 2012;172(17):1350–1351. doi:10.1001/archinternmed.2012.3223
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: